Anuj Shah

Credit Suisse on Thursday issued a report on Pharmacyclics, Inc. (NASDAQ: PCYC) a day after the company soared 17 percent following acquisition rumors. Credit Suisse downgraded Pharmacyclics from Outperform to Neutral and raised its price target from $163 to $233. A report  issued by...